Cloudbreak has successfully achieved the primary endpoint in its clinical trial for a new drug aimed at treating pterygium, a growth of tissue on the eye's surface. This milestone indicates that the drug has met the necessary criteria set forth by the trial's design, which is a significant step in the development process. The company is expected to analyze the data further and share results with the medical community as it progresses toward potential regulatory submission.
Related Articles
Don't miss out on breaking stories and in-depth articles.